{"id":"prophylactic-valganciclovir","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valganciclovir is rapidly converted to ganciclovir in the body, which then selectively inhibits CMV DNA polymerase by competing with deoxyguanosine triphosphate. This prevents viral DNA synthesis and replication. When used prophylactically, it reduces the risk of CMV disease in high-risk immunocompromised populations such as transplant recipients.","oneSentence":"Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:55.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients)"}]},"trialDetails":[{"nctId":"NCT05708508","phase":"PHASE3","title":"Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-28","conditions":"Kidney Transplant Infection","enrollment":144},{"nctId":"NCT07294547","phase":"NA","title":"Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-11-27","conditions":"Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis","enrollment":80},{"nctId":"NCT07203664","phase":"PHASE4","title":"Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario La Paz","startDate":"2025-10-30","conditions":"Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients","enrollment":30},{"nctId":"NCT02538172","phase":"NA","title":"Cell-mediated Immunity for Prevention of CMV Disease","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2015-10","conditions":"Cytomegalovirus Infections","enrollment":195},{"nctId":"NCT03123627","phase":"PHASE3","title":"Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2016-08-23","conditions":"Kidney Transplant Infection","enrollment":150},{"nctId":"NCT04278547","phase":"PHASE4","title":"Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2020-06-12","conditions":"Heart Transplant Infection, CMV Infection","enrollment":188},{"nctId":"NCT02503982","phase":"PHASE4","title":"Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2014-12","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":13},{"nctId":"NCT00374686","phase":"NA","title":"Study of Prophylactic Vs Preemptive Valganciclovir","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-03","conditions":"Cytomegalovirus Infection","enrollment":120},{"nctId":"NCT00364052","phase":"","title":"Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2006-08","conditions":"Liver Transplantation","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valcyte"],"phase":"marketed","status":"active","brandName":"prophylactic Valganciclovir","genericName":"prophylactic Valganciclovir","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients. Used for Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}